SCHEMBL25858341

SCHEMBL25858341

CC(=O)N[C@@H]1[C@H]2CC[C@H]1N(c1nnc(Br)s1)C2

nearest known ligand 0.34

Predicted protein targets (top 1)

geneUniProtsupporting neighboursconfidence
GLS O94925 3/20 0.34

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL21797680 0.83 GLS (0.41) GLS
SCHEMBL21738014 0.83 GLS (0.41) GLS
SCHEMBL21738050 0.83 GLS (0.41) GLS
SCHEMBL21797678 0.83 GLS (0.41) GLS
SCHEMBL30843360 0.78 GLS (0.40) GLS
SCHEMBL21738019 0.78 GLS (0.40) GLS
SCHEMBL21797357 0.78 GLS (0.40) GLS
SCHEMBL21797358 0.78 GLS (0.40) GLS
SCHEMBL21738018 0.78 GLS (0.31) GLS
SCHEMBL21738028 0.75 GLS (0.41) GLS

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-11702414-B2 Thiadiazole IRAK4 inhibitors GILEAD SCIENCES, INC. (US) 2023-07-18 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-11702414-B2 Thiadiazole IRAK4 inhibitors IRAK4, IRAK3, IRAK1 GLS 2423/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.